Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET | Source: Affimed N.V. The combination of…
Tag: Nasdaq:AFMD